Bio-Techne (NASDAQ:TECH – Get Free Report) posted its quarterly earnings results on Wednesday. The biotechnology company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.45 by $0.03, Briefing.com reports. Bio-Techne had a net margin of 19.58% and a return on equity of 14.21%. The business had revenue of $303.43 million for the quarter, compared to analysts’ expectations of $292.36 million. During the same period in the prior year, the company posted $0.47 EPS. The business’s revenue for the quarter was up 3.2% on a year-over-year basis.
Bio-Techne Trading Up 0.7 %
NASDAQ:TECH traded up $0.52 on Thursday, reaching $73.98. The stock had a trading volume of 250,303 shares, compared to its average volume of 1,087,834. Bio-Techne has a 12-month low of $51.79 and a 12-month high of $89.91. The firm’s fifty day moving average is $69.57 and its two-hundred day moving average is $68.44. The company has a debt-to-equity ratio of 0.23, a current ratio of 4.37 and a quick ratio of 3.03. The company has a market cap of $11.63 billion, a price-to-earnings ratio of 53.53, a P/E/G ratio of 7.87 and a beta of 1.23.
Bio-Techne Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, May 24th. Shareholders of record on Monday, May 13th will be issued a $0.08 dividend. The ex-dividend date is Friday, May 10th. This represents a $0.32 dividend on an annualized basis and a yield of 0.43%. Bio-Techne’s dividend payout ratio (DPR) is 23.19%.
Wall Street Analysts Forecast Growth
Get Our Latest Report on Bio-Techne
Insider Activity
In other news, Director Roeland Nusse sold 10,400 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $76.98, for a total transaction of $800,592.00. Following the completion of the transaction, the director now owns 43,097 shares of the company’s stock, valued at approximately $3,317,607.06. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 4.45% of the company’s stock.
Bio-Techne Company Profile
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.
Further Reading
- Five stocks we like better than Bio-Techne
- ETF Screener: Uses and Step-by-Step Guide
- Meta Stock: 3 Reasons This Stumble Is a Golden Buying Opportunity
- How to Buy Cheap Stocks Step by Step
- 3 Staples Stocks to Cushion Lower Consumer Sentiment
- 3 Fintech Stocks With Good 2021 Prospects
- Zillow’s Earnings Dip: An Opportunity for Visionaries
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.